The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
But not every company with momentum is a long-term winner, and plenty of investors have lost money betting on short-term fads. On that note, here are two stocks we think live up to the hype and one best left ignored.
One Stock to Sell:
Biogen (BIIB)
One-Month Return: +3.3%
Founded in 1978 and pioneering treatments for some of medicine's most complex challenges, Biogen (NASDAQ: BIIB) develops and markets therapies for neurological conditions, including multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, and rare diseases.
Why Does BIIB Fall Short?
- Customers postponed purchases of its products and services this cycle as its revenue declined by 3% annually over the last five years
- Falling earnings per share over the last five years has some investors worried as stock prices ultimately follow EPS over the long term
- Eroding returns on capital suggest its historical profit centers are aging
At $224.63 per share, Biogen trades at 16.5x forward P/E. Check out our free in-depth research report to learn more about why BIIB doesn’t pass our bar.
Two Stocks to Buy:
Mastercard (MA)
One-Month Return: +2.5%
Recognizable by its iconic "Priceless" advertising campaign that has run in over 120 countries, Mastercard (NYSE: MA) operates a global payments network that connects consumers, financial institutions, merchants, and businesses, enabling electronic transactions and providing payment solutions.
Why Do We Love MA?
- Annual revenue growth of 16.1% over the past five years was outstanding, reflecting market share gains this cycle
- Share repurchases have amplified shareholder returns as its annual earnings per share growth of 22.1% exceeded its revenue gains over the last five years
- Industry-leading 182% return on equity demonstrates management’s skill in finding high-return investments
Mastercard is trading at $588.84 per share, or 27x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
ConocoPhillips (COP)
One-Month Return: -1.7%
Operating the famous Prudhoe Bay field discovered in 1968 that transformed Alaska's economy, ConocoPhillips (NYSE: COP) explores for and produces crude oil, natural gas, and liquefied natural gas across North America, Europe, Asia, and Africa.
Why Is COP a Top Pick?
- Market share has increased this cycle as its 10.1% annual revenue growth over the last ten years was exceptional
- Unparalleled revenue scale of $65.28 billion gives it advantageous pricing and terms with suppliers
- COP is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders
ConocoPhillips’s stock price of $134.30 implies a valuation ratio of 12.3x forward P/E. Is now the right time to buy? See for yourself in our full research report, it’s free.
Stocks We Like Even More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
